Key statistics
As of last trade Longboard Pharmaceuticals Inc (LBPH:NMQ) traded at 59.77, -0.30% below its 52-week high of 59.95, set on Nov 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 59.80 |
---|---|
High | 59.83 |
Low | 59.77 |
Bid | 59.77 |
Offer | 59.78 |
Previous close | 59.77 |
Average volume | 822.35k |
---|---|
Shares outstanding | 39.05m |
Free float | 34.02m |
P/E (TTM) | -- |
Market cap | 2.33bn USD |
EPS (TTM) | -2.24 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 18:05 GMT.
More ▼
- Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
- Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
- Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
- Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
- Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
- Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
More ▼